# Cavity-control of bright and dark interlayer excitons in van der Waals heterostructures

Article · Michael Förg, Léo Colombier, Robin K. Patel, Jessica Lindlau, Aditya D. Mohite, Hisato Yamaguchi, David Hunger, Alexander Högele

- Archive id: arxiv:1710.00990
- Published: 2017-10-03
- Venue: Nat. Commun. 10, 3697 (2019)
- DOI: https://doi.org/10.1038/s41467-019-11620-z
- arXiv: https://arxiv.org/abs/1710.00990
- Citations: 87
- Source URL: https://arxiv.org/abs/1710.00990
- PDF: https://arxiv.org/pdf/1710.00990
- Provenance: arxiv

## Abstract

Monolayer (ML) transition metal dichalcogenides (TMDs) integrated in optical microcavities host exciton-polaritons as a hallmark of the strong light-matter coupling regime. Analogous concepts for hybrid light-matter systems employing spatially indirect excitons with a permanent electric dipole moment in heterobilayer (HBL) crystals promise realizations of exciton-polariton gases and condensates with immanent dipolar interactions. Here, we identify optical signatures of spatially indirect momentum-bright and momentum-dark interlayer excitons in vertical MoSe$\_2$-WSe$\_2$ heterostructures and implement cavity-control of both exciton manifolds. Our experiments quantify the strength of light-matter coupling for both zero and finite momentum excitons residing in Moiré superlattices of TMD HBLs and demonstrate that both exciton species are susceptible to Purcell enhancement in cavity-modified photonic environments. Our results form the basis for further developments of dipolar exciton-polariton gases and condensates in hybrid cavity -- van der Waals heterostructure systems.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [2D Materials & Van der Waals Heterostructures](https://space-kitty.com/topics/2d-materials)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.